ARS Pharma (SPRY) Q1 2026 Earnings Transcript

ARS Pharmaceuticals reported Q1 2026 revenue of $22.7 million, with U.S. net product revenue for neffy at $17.5 million, more than doubling year over year as prescriptions tripled. Management highlighted ~90% commercial coverage, 9-state unrestricted Medicaid access, a new $199 retail cash-price program, and a CVS Caremark proposal that could remove prior authorization for an estimated 15% of covered lives. The company ended the quarter with $201 million in cash and reiterated a path to cash breakeven by mid-2027.

Analysis

The key inflection is not headline demand; it is distribution friction collapsing. neffy’s economics become far more attractive if the company converts a meaningful slice of rejected or delayed scripts into immediate fills at retail, because that reduces abandonment and, more importantly, converts prescriber skepticism into habit formation. The second-order effect is that access gains can compound through workflow: once staff trusts the coverage/cash-price path, each incremental prescription becomes less time-consuming, which should matter more in a high-volume, refill-driven category than another round of pure awareness spending.

The CVS/Caremark decision is the near-term catalyst that can re-rate the stock over the next 4-8 weeks, but the bigger driver into late summer is whether the company can sustain a visible improvement in conversion at the pharmacy counter before back-to-school peak. If the formulary change lands, the upside is not just more covered lives; it is a step-change in “prescribe-and-fill” confidence that should also lift refill behavior into 2027. That said, the bear case is that management is implicitly assuming a smooth pass-through from access to utilization, while real-world adoption may still be gated by prescriber inertia and payer rejections outside the major plans.

The financial setup is better than the market likely expects, but the path to breakeven is still execution-sensitive. The company’s burn appears manageable only if gross-to-net stays near target and SG&A discipline holds while revenue ramps seasonally; any delay in CVS or slower retail conversion could keep losses elevated into the second half of 2026. The contrarian miss is that the market may be underestimating how much of the value is being driven by operational simplification rather than medical differentiation, which typically means the stock can rerate quickly on small process wins but also gives back gains fast if conversion metrics disappoint.

Key Decisions for Investors

• Long SPRY into the next 4-6 weeks ahead of the CVS/Caremark decision; upside is a multiple expansion on formulary confirmation, while downside is capped by cash runway but could mean a sharp de-rating if approval slips.
• Use call spreads in SPRY for the July/August back-to-school window; the cleanest path to upside is a summer usage acceleration, and options isolate the binary access catalyst with limited capital at risk.
• Pair trade: long SPRY / short CVS over the next 1-3 months; if neffy wins meaningful access without prior auth, CVS may face modest administrative/margin friction while SPRY gets the direct benefit of lower abandonment and higher conversion.
• If SPRY rallies hard on CVS headlines, trim into strength rather than chase; the stock is now a second-order execution story, so the risk/reward worsens if the market fully prices in the access win before refill data confirms it.